Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study.

Bouchot O, Soret JY, Jacqmin D, Lahlou N, Roger M, Blumberg J

Hormone research1 Jan 1998Cited by 16 (Europe PMC)

PMID9701702DOI10.1159/000023241PepBankPUB-09701702

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with advanced prostate carcinoma, triptorelin achieved surgical castration-range testosterone after a mean of 22 days.
In plain wordsIn patients with advanced prostate cancer, triptorelin reduced testosterone to surgical castration levels after a mean of 22 days.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTime to castration-range testosterone
Study
n = 14
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg · 3 monthsAs given in this study (human).
Measurements
Time to castration-range testosterone
22 days
after one injection
Source sentences
Summary
After one single injection, the mean time to reach the surgical castration testosterone range is 22 days, and this effective testosterone suppression is maintained for the 3-month therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamics and the pharmacokinetic characteristics of a new longer-acting formulation containing 11.25 mg of triptorelin (Decapeptyl) to be administered every 3 months were evaluated in 14 patients with advanced prostate carcinoma.
Report a problemFND-0970170201
02HumanNon-randomized trialEfficacy outcome
In patients with advanced prostate carcinoma, testosterone suppression after triptorelin persisted for the 3-month therapy.
In plain wordsIn patients with advanced prostate cancer, triptorelin maintained testosterone suppression throughout treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseDuration of testosterone suppression
Study
n = 14
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg · 3 monthsAs given in this study (human).
Source sentences
Summary
After one single injection, the mean time to reach the surgical castration testosterone range is 22 days, and this effective testosterone suppression is maintained for the 3-month therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamics and the pharmacokinetic characteristics of a new longer-acting formulation containing 11.25 mg of triptorelin (Decapeptyl) to be administered every 3 months were evaluated in 14 patients with advanced prostate carcinoma.
Report a problemFND-0970170202
03HumanNon-randomized trialPharmacokinetics
In patients with advanced prostate carcinoma, the initial triptorelin plasma surge reached 35.70 ng/ml at 2.5 hours.
In plain wordsIn patients with advanced prostate cancer, triptorelin showed an early peak in blood levels after injection.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableInitial triptorelin plasma surge
Study
n = 14
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
11.25 mg · 3 monthsAs given in this study (human).
Measurements
Plasma surge
35.7 ng/ml
2.5 h after injection
Source sentences
Summary
After a first plasma surge (35.70 ng/ml) occurring 2.5 h after injection and a rise between day 17 and day 31 (maximum on day 24: 0.32 ng/ml), the mean triptorelin plasma level is stable (0.06 +/- 0.05 ng/ml) and maintained until day 91.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamics and the pharmacokinetic characteristics of a new longer-acting formulation containing 11.25 mg of triptorelin (Decapeptyl) to be administered every 3 months were evaluated in 14 patients with advanced prostate carcinoma.
Report a problemFND-0970170203
04HumanNon-randomized trialPharmacokinetics
In patients with advanced prostate carcinoma, a secondary triptorelin plasma rise peaked at 0.32 ng/ml on day 24.
In plain wordsIn patients with advanced prostate cancer, triptorelin blood levels showed a second rise after injection.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSecondary triptorelin plasma rise
Study
n = 14
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
11.25 mg · 3 monthsAs given in this study (human).
Measurements
Secondary peak
0.32 ng/ml
day 24
Source sentences
Summary
After a first plasma surge (35.70 ng/ml) occurring 2.5 h after injection and a rise between day 17 and day 31 (maximum on day 24: 0.32 ng/ml), the mean triptorelin plasma level is stable (0.06 +/- 0.05 ng/ml) and maintained until day 91.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamics and the pharmacokinetic characteristics of a new longer-acting formulation containing 11.25 mg of triptorelin (Decapeptyl) to be administered every 3 months were evaluated in 14 patients with advanced prostate carcinoma.
Report a problemFND-0970170204
05HumanNon-randomized trialPharmacokinetics
In patients with advanced prostate carcinoma, mean triptorelin plasma concentration stabilized at 0.06 +/- 0.05 ng/ml until day 91.
In plain wordsIn patients with advanced prostate cancer, triptorelin blood levels remained stable through day 91.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableStable triptorelin plasma concentration
Study
n = 14
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
11.25 mg · 3 monthsAs given in this study (human).
Measurements
Mean stable concentration
0.06 ng/ml
until day 91; reported as 0.06 +/- 0.05
Source sentences
Summary
After a first plasma surge (35.70 ng/ml) occurring 2.5 h after injection and a rise between day 17 and day 31 (maximum on day 24: 0.32 ng/ml), the mean triptorelin plasma level is stable (0.06 +/- 0.05 ng/ml) and maintained until day 91.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamics and the pharmacokinetic characteristics of a new longer-acting formulation containing 11.25 mg of triptorelin (Decapeptyl) to be administered every 3 months were evaluated in 14 patients with advanced prostate carcinoma.
Report a problemFND-0970170205
06HumanNon-randomized trialSafety outcome
In patients with advanced prostate carcinoma, the 3-month triptorelin formulation was well tolerated both locally and systemically.
In plain wordsIn patients with advanced prostate cancer, the triptorelin formulation was well tolerated locally and throughout the body.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedLocal and systemic tolerability
Study
n = 14
Outcome group
Adverse events · Whole body
Studied dose
11.25 mg · 3 monthsAs given in this study (human).
Source sentences
Summary
This new formulation was well tolerated both locally and systemically.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamics and the pharmacokinetic characteristics of a new longer-acting formulation containing 11.25 mg of triptorelin (Decapeptyl) to be administered every 3 months were evaluated in 14 patients with advanced prostate carcinoma.
Report a problemFND-0970170206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.